The Centers for Medicare & Medicaid Services has selected 61 applicants for the Value in Opioid Use Disorder Treatment Demonstration, a four-year Medicare payment model beginning this month for selected health care providers who agree to participate.

Participants will test whether a new care management fee and performance-based incentive payment for OUD treatment services reduces hospitalizations and improves health outcomes for Medicare fee-for-service patients with OUDs, including those dually eligible for Medicaid. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 authorizes $10 million annually in fiscal years 2021-2024 to pay for the treatment services. 

Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The Centers for Medicare & Medicaid Services has released its fiscal year 2025 Program for Evaluating Payment Patterns Electronic Reports, or PEPPERs, for…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
The Centers for Medicare & Medicaid Services has begun collecting private payor rate data through its Fee-for-Service Data Collection System Clinical Lab…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better…